Acute Myeloid Leukemia (AML) Treatment Market Share

  • Report ID: 2894
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Acute Myeloid Leukemia (AML) Treatment Market Share

North American Market Forecasts

North America in acute myeloid leukemia market is estimated to hold over 40% revenue share by the end of 2037. The growth of this market in the region will be impelled by the growing R&D and product launches. This has led to the discovery of more effective therapies in the field of acute myeloid leukemia.

Besides this, the increasing incidence of acute myeloid leukemia in the United States is likely to drive market expansion. For instance, there were 60,650 new instances of leukemia cancer in the US in 2022, with 24,000 of those cases projected to result in death.

Canada has progressively increased AML incidence rates, with an estimated average of 30.61 cases per million people per year.

APAC Market Statistics

The Asia Pacific acute myeloid leukemia market is set to grow significantly during the period between 2024-2037. There is an increasing prevalence of AML in the region on account of population growth. As a result, there is a growing acceptability of novel treatments and therapies leading to more people obtaining timely therapy.

As per UNFPA, approximately 4.3 billion people, or 60% of the world's population, live in the Asia and Pacific area.

China is home to one in five children worldwide who suffer from acute lymphoblastic leukemia, and more than 55% of the 75.3 thousand new cases of leukemia in China each year are AML patients.

The majority of adult leukemia cases in Korea are caused by acute myeloid leukemia (AML), a representative blood malignancy, which has been a significant national public health concern.

Substantial progress has been made recently in the identification and management of AML in Japan, leading to the generation of a need for novel and more potent AML treatments. AML and other diseases such as multiple myeloma are key areas of attention for the Japanese government, which is constantly trying to improve access to current medications while also sponsoring research into novel AML treatments.

Research Nester
Acute Myeloid Leukemia Market Size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2894
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of acute myeloid leukemia is assessed at USD 3.7 billion.

The acute myeloid leukemia market size was valued at USD 3.41 billion in 2024 and is likely to cross USD 12.63 billion by 2037, expanding at more than 10.6% CAGR during the forecast period i.e., between 2025-2037. Rising owing to the aging population across the globe will boost the market growth..

North America industry is expected to dominate majority revenue share of 40% by 2037, due to growing R&D and product launches in the region.

The major players in the market include Pfizer Inc., Novartis International AG, Celgene Corporation, Bristol-Myers Squibb Company, Amgen Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, Sanofi-Aventis (Genzyme Corporation), Sunesis Pharmaceutical Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample